Navigation Links
Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation
Date:5/7/2008

GREENWICH, Conn., May 7 /PRNewswire-FirstCall/ -- Oracle Healthcare Acquisition Corp. (the "Company") (OTC Bulletin Board: OHAQ) announced today its stockholders voted to approve the dissolution of the Company and its proposed plan of liquidation, as presented in the Company's proxy statement dated April 16, 2008, at the special meeting of stockholders held on May 7, 2008.

As previously announced, the Company has set May 7, 2008 as the record date for determining the stockholders entitled to receive a liquidating distribution, if any, from the trust account in which the proceeds from the Company's initial public offering were placed and the Company expects to pay the liquidating distribution, if any, on or around May 12, 2008. The Company has filed a certificate of dissolution with the Secretary of State of the State of Delaware for the purpose of effecting its dissolution and has filed a Certificate of Termination of Registration on Form 15 with the Securities and Exchange Commission for the purpose of deregistering its securities under the Securities Exchange Act of 1934, as amended. As a result, the Company will no longer be a public reporting company and its securities will cease trading on the OTC Bulletin Board.

The Company filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on Schedule 14A on April 16, 2008 regarding the dissolution and Plan of Liquidation of the Company. Stockholders and investors are encouraged to read the definitive proxy statement because it contains important information regarding the dissolution and Plan of Liquidation of the Company. Investors are able to obtain free copies of the proxy statement as well as other filed documents containing information about the Company at http://www.sec.gov, the SEC's Web site.

Forward Looking Statements:

This press release contains includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports, including the Form 10-K for the year ended December 31, 2007 and definitive proxy statement on Schedule 14A filed with the SEC on April 16, 2008.

Contact: President and Chief Operating Officer

Oracle Healthcare Acquisition Corp.

(203) 862-7900


'/>"/>
SOURCE Oracle Healthcare Acquisition Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Oracle Healthcare Acquisition Corp. Changes Record Date and Date of Special Meeting to Consider and Vote on Dissolution and Plan of Liquidation
2. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
3. Oracle Introduces Remote Data Capture Onsite 4.5.3 With Extensive New Functionality for Investigative Site Personnel
4. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
5. Oracle Helps Mayo Clinic Improve Information Management
6. TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM)
7. Care Today, Gone Tomorrow: Hospital Advocates Plan State House Rally May 12 to Protest Healthcare Cuts
8. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
9. HMS Holdings Corp. to Present at Bank of America 2008 Healthcare Conference
10. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
11. Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: